FeesSafety
Pluang+

Montauk Renewables delays capital spending, seeks credit amendments amid swine waste project delays

Company Fundamentals
19 Nov 2026, 02:27 WIB
The Motley Fool
View Source
Neutral
Montauk Renewables delays capital spending, seeks credit amendments amid swine waste project delays

Montauk Renewables deferred up to $120 million in capital spending and is negotiating credit facility amendments due to operational delays at its North Carolina swine waste facility, which pose short-term debt covenant risks. The company expects to spend about $15 million and take three months to enhance operations there. Meanwhile, its GreenWave joint venture distributed 1.1 million Renewable Identification Numbers, boosting revenue. Montauk reaffirmed its full-year renewable natural gas production and revenue outlook despite market pricing challenges, focusing on liquidity and expanding agricultural renewable energy projects.

Montauk Renewables is managing operational delays and credit negotiations while maintaining its renewable natural gas outlook. For readers following the Energy sector, here is Pluang's market snapshot as of Nov 19, 2026 07:11 WIB: Of 79 priced US Energy stocks, 8 rose and 71 fell. Notable movers include SM Energy Company at USD 28.81 with a 1-day change of -5.32%, Marathon Petroleum Corp at USD 374.35 with 99% sell order activity, and Valero Energy Corporation at USD 345.78 with a 58% buy order activity and a typical hold time of 56 days on Pluang.

More News

Micron's strong growth and rising stock price hint at a possible future stock split.

Micron's strong growth and rising stock price hint at a possible future stock split.

Micron Technology is showing strong financial growth, driven by its crucial role in AI infrastructure and multiyear deals with key tech companies. The company recently beat revenue expectations with a 379% year-over-year increase and projects even be...

Company Fundamentals
Bullish
1 hour ago
FDA approves Livsayis™, first siRNA therapy for generalized myasthenia gravis, offering new treatment option.

FDA approves Livsayis™, first siRNA therapy for generalized myasthenia gravis, offering new treatment option.

The FDA has approved Livsayis™ (cemdisiran), the first and only siRNA therapy for adults with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor antibody-positive. This subcutaneous treatment, administered four times a year, targ...

Market News
Bullish
1 hour ago
Elauwit reports 66% growth in monthly recurring revenue to $539K, cutting expenses and expanding managed Wi-Fi networks.

Elauwit reports 66% growth in monthly recurring revenue to $539K, cutting expenses and expanding managed Wi-Fi networks.

Elauwit announced a 66% year-over-year increase in monthly recurring revenue to $539,000 by the end of Q3 2026, driven by long-term contracts for managed Wi-Fi in apartment communities. The company also reduced operating expenses by 19% sequentially ...

Company Fundamentals
Bullish
1 hour ago
Montauk Renewables delays capital spending, seeks credit amendments amid operational challenges.

Montauk Renewables delays capital spending, seeks credit amendments amid operational challenges.

Montauk Renewables deferred up to $120 million in capital spending and is negotiating credit facility amendments due to operational delays at its North Carolina swine waste project. These delays have created short-term risks for debt covenants, requi...

Company Fundamentals
Neutral
1 hour ago
Palantir's revenue soars past $2B, outpacing UiPath's slower, seasonal growth in AI software sales.

Palantir's revenue soars past $2B, outpacing UiPath's slower, seasonal growth in AI software sales.

Palantir Technologies has shown rapid quarter-over-quarter revenue growth, reaching $2.3 billion in Q3 2026, driven by strong commercial adoption of its AI platform and expansion beyond government contracts. In contrast, UiPath's revenue growth is mo...

Market News
Bullish
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App